Method for the treatment of chronic bronchitis

 

(57) Abstract:

The invention relates to medicine, namely to pulmonology and physiotherapy. Transcutaneous effect of low-intensity infrared laser radiation, gallium arsenide nature with the aid of a laser therapeutic units on the field light on the rear surface of the chest, intercostal space. When a patient complains of non-productive cough, chest pain associated with breathing and cough, when the forced expiratory volume in the first second (FEV1)>1.5 l is irradiated with the first light with a frequency of 600 Hz, then the frequency of 1500 Hz. With complaints of productive cough and FEV1>1.5 l is irradiated with light with a frequency of 600 Hz. Exposure dose for each light upon irradiation with a frequency of 600 Hz must be 0.1 MJ/cm2, 1500 Hz to 0.05 MJ/cm2. When a patient complains of a productive cough and FEV1<1.5 l is irradiated with the first light with a frequency of 600 Hz, then the frequency of 80 Hz. Exposure to light with each frequency should be of 0.01 MJ/cm2. The exposure time of each frequency calculated by the formula: where D is the exposure dose for each frequency j/cm2; P - average pulse power pack the irradiation, cm2. The method provides the dose of laser radiation based on the reserve capacity of the body, which increases the efficiency and reduces the treatment time.

The invention relates to medicine, namely to pulmonology and physiotherapy for the treatment of chronic bronchitis (CB).

A prototype of the invention taken treatment HB by multiple session transcutaneous effects of low-intensity infrared laser radiation of gallium arsenide nature in the field of vascular bundle and the lungs, including the vascular bundle in the second and Terem the intercostal space to the left and right of the sternum with a pulse frequency of 80 Hz for 2 min on each side, light on the rear surface of the chest, intercostal space for 5 min on each light, with a frequency 1017-1356 Hz when the patient complains hacking non-productive cough, chest pain associated with breathing and coughing, lung disorders of respiratory function, or frequency 254-339 Hz with complaints of productive cough with mucopurulent sputum and moderate disorders of respiratory function, or with a frequency that belongs to the interval 63-84 Hz, - if the patient complains of a productive cough with mucopurulent the b treatment of chronic bronchitis: a Russian Patent for invention № 2180250 from 10.03.2002).

The disadvantage of the prototype is the lack of a dose of laser radiation on the exposure dose. Furthermore, the method does not take into account the sensitivity of lung tissue to laser radiation, do not allow differentiation therapy on duration of exposure. These drawbacks reduce the effectiveness of treatment HB.

The technical result is to increase the effectiveness of treatment HB.

The technical result is achieved by including multiple session transcutaneous influence of low-intensity infrared laser radiation of gallium arsenide nature on the lungs on the rear surface of the chest in the intercostal space, the method of treatment HB involves the irradiation of light with a frequency pulses, taking into account the sensitivity of lung tissue to laser radiation, the clinical features of the disease, forced expiratory volume in the first second (FEV 1), and in the course of irradiation, the irradiator constantly move without interruption from the skin, so that the exposure time of one point does not exceed 2 seconds, session duration exposure set by calculation, taking into account the values of FEV 1.

When a patient complains unproductive then frequency Hz.

With complaints of productive cough and FEV1>1.5 l is irradiated with light with a frequency of 600 Hz.

When a patient complains of a productive cough and OFF,5 l is irradiated with the first light with a frequency of 600 Hz, then the frequency of 80 Hz.

The duration of exposure (t) calculated by the formula:

where D is the exposure dose, j/cm2;

P - average pulse power of the beam, W;

- pulse duration, s;

f is the pulse frequency, Hz;

t is the exposure time, s;

S - area of exposure, see

The duration of exposure is calculated from the values of FEV 1. When FEV1>1.5 l exposure dose for each light upon irradiation with a frequency of 600 Hz must be 0.1 MJ/cm 1500 Hz to 0.05 MJ/cm; when OFF,5 l each frequency of 0.01 MJ/cm in one lung. Thus, in patients with FEV1>1.5 l and nonproductive cough exposure dose per session - 0.3 MJ/cm2if productive cough is 0.2 MJ/cm2when OFF,5 l of 0.02 MJ/cm2.

It is known that infrared laser radiation of low intensity frequency of 80 Hz is most effective for stimulation of regenerative processes, frequency of 600 G is evasee action and has influence on the course of reflex processes. At the same time you know that achieving FEV 1 values of 1.5 litres or less in the bronchi of patients with HB prevail scar processes; at higher FEV 1 and a productive cough in the bronchi is registered with an active inflammatory process, if non-productive cough in the formation of bronchial obstruction predominates reflex component (bronchospasm), and pain restricts breathing and expectoration of sputum. Therefore, the frequency selection ensures that the clinical features of the disease.

It was also established that light is most sensitive to a frequency of 600 Hz. Therefore, the irradiation light with this frequency provides the sensitivity of lung tissue to laser radiation.

The value of FEV 1 reflects the reserve capacity of the organism of the patient HB. Therefore, the choice of the exposure dose corresponding to the severity of decline of FEV 1 in a patient, provides the dose of laser radiation based on the reserve capacity of the organism.

The duration of the exposure as determined in accordance with the exposure dose and the irradiation area, allows to differentiate therapy on the duration of exposure for each patient, because the area on which elicina FEV 1 each particular person.

Examples of practical implementation of the method.

1. Patient Y., 44 years. Hospitalized with exacerbation of HB. Complains about hacking unproductive cough, pain in the chest when breathing or coughing. The diagnosis of HB set 5 years ago. On the chest x-ray data for pneumonia no. FEV1-1,8 l

Therefore, the patient C., in accordance with the proposed method, assigned daily session transcutaneous influence of low-intensity infrared laser radiation of gallium arsenide nature with the aid of a laser therapeutic settings “Mustang-024”, power output 5 watts, on the area of the lung area of 190 cm2in series with the pulse repetition rate of 600 Hz for 2 min 7 s, then with a frequency of 1500 Hz for 25 with constant movement of the feed within the zone without separation from the skin so that the exposure time of one point does not exceed 2 C. FEV 1 after treatment 2,2 l (i.e., the growth rate exceeds 200 ml).

2. Patient K., 68 years. Hospitalized with exacerbation of HB. Worried about the cough with mucopurulent sputum, FEV 1, 1.5 l

Therefore, the patient K., in accordance with the proposed method, assigned daily session TransCut sernai therapeutic settings “Mustang-024”, power output 5 watts, on the area of the lung area of 160 cm2with a pulse repetition rate of 600 Hz for 11 with constant movement of the feed within the zone without separation from the skin so that the exposure time of one point does not exceed 2, then - with a frequency of 80 Hz for 1 min 20 C. FEV 1 after treatment 1.9 l (growth rate exceeds 200 ml).

The results of treatment of patients with HB according to the method of the prototype and the proposed method showed that the treatment according to the method of the prototype (101 people) increase in FEV 1 by 13.6% to 10 session received 72% of patients and in the treatment by the proposed method (42 people) 14.8% - 87%, i.e., advanced to the way the prototype is 15%. Therefore, in the treatment by the proposed method increases the number of patients with a significant increase in FEV 1 to 10 days of treatment, i.e., the proposed method increases the effectiveness of the treatment.

Thus, the proposed method assumes the dose of laser radiation depending on the sensitivity of lung tissue to laser radiation and clinical features of the disease, the values of FEV 1, exposure dose, the effectiveness of the treatment HB stomach due to a larger increase in FEV 1 in a larger number of patients.

The advantage of the invention is to reduce the duration of temporary disability, to improve the quality of rehabilitation of patients.

Method for the treatment of chronic bronchitis, including transcutaneous influence of low-intensity infrared laser radiation of gallium arsenide nature with the aid of a laser therapeutic units on the field light on the rear surface of the chest, intercostal space, characterized in that when a patient complains of non-productive cough, chest pain associated with breathing and cough, when the forced expiratory volume in the first second (FEV1)>1.5 l is irradiated with the first light with a frequency of 600 Hz, then the frequency of 1500 Hz, with complaints of productive cough and FEV1>1.5 liters is irradiated with light with a frequency of 600 Hz, and exposure dose for each light upon irradiation with a frequency of 600 Hz must be 0.1 MJ/cm2, 1500 Hz to 0.05 MJ/cm2when a patient complains of a productive cough and FEV1<1.5 l is irradiated with the first light with a frequency of 600 Hz, then the frequency of 80 Hz, and exposure dose for each light to each frequency should be of 0.01 MJ/cm2the duration of exposure to each frequency calculated by the formula

,

where D is the exposure dose, j/cm2;

P - average pulse is of Alisov, Hz;

t is the exposure time, s;

S - area of exposure, cm2.

 

Same patents:
The invention relates to medicine, namely to reducing treatment in traumatology and orthopedics, and can be used in patients with arthrosis, osteochondrosis of the spine, herniated intervertebral disc, epicondylitis, bruises, syndrome title, carpal tunnel, etc

The invention relates to medicine, gynecology

The invention relates to medicine, gynecology, in particular, can be used in the treatment of background and precancerous diseases of the cervix during the rehabilitation period after local destruction
The invention relates to medicine, namely to gynecology
The invention relates to medicine, in particular to vascular surgery for the treatment of trophic ulcers of the lower limbs venous nature
The invention relates to medicine, namely to the way fluorescent diagnostics of malignant lesions of organs pleural or abdominal cavity
The invention relates to medicine, in particular to urology, and can be used for the treatment of hydrocele
The invention relates to medicine, magnitolazeroterapii
The invention relates to medicine, namely to physical therapy and urology

FIELD: medicine.

SUBSTANCE: method involves introducing 0.1-0.3 ml of photosensitizing gel preliminarily activated with laser radiation, after having removed neovascular membrane. The photosensitizing gel is based on a viscoelastic of hyaluronic acid containing khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-2% by mass. The photosensitizing gel is in vitro activated with laser radiation having wavelength of 661-666 nm during 3-10 min with total radiation dose being equal to 100-600 J/cm2. The gel is introduced immediately after being activated. To compress the retina, vitreous cavity is filled with perfluororganic compound or air to be further substituted with silicon oil. The operation is ended with placing sutures on sclerotomy and conjunctiva areas. Compounds like chealon, viscoate or hyatulon are used as viscoelastic based on hyaluronic acid. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity.

EFFECT: excluded recurrences of surgically removed neovascular membrane and development of proliferative retinopathy and retina detachment; retained vision function.

3 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: method involves making incision in conjunctiva and Tenon's capsule of 3-4 mm in size in choroid hemangioma projection to sclera 3-4 mm far from limb. Tunnel is built between sclera and Tenon's capsule to extrasclerally introduce flexible polymer magnetolaser implant through the tunnel to the place, the choroid hemangioma is localized, after performing transscleral diaphanoscopic adjustment of choroid hemangioma localization and size, under visual control using guidance beam. The implant has permanent ring-shaped magnet in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 2-3 mTesla units intensity. It is arranged with its north pole turned towards the choroid hemangioma so that extrascleral implant laser radiator disposition. The other end of the implant is sutured to sclera 5-6 mm far from the limb with two interrupted sutures through prefabricated openings. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. 0.1-1% khlorin solution is injected in intravenous bolus dose of 0.8-1.1 mg/kg as photosensitizer and visual control of choroid hemangioma cells fluorescence and fluorescent diagnosis methods are applied. After saturating choroid hemangioma with the photosensitizer to maximum level, transscleral choroid hemangioma laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm with total radiation dose being equal to 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the intraocular neoplasm, repeated laser irradiation of the choroid hemangioma is carried out with radiation dose of 30-60 J/cm2.

EFFECT: enhanced effectiveness of treatment.

4 cl

FIELD: medicine.

SUBSTANCE: method involves creating tunnel between sclera and Tenon's capsule in intraocular neoplasm projection. Intraocular neoplasm localization and size is adjusted by applying transscleral diaphanoscopic examination method. 0.1-0.3 ml of photosensitizing gel based on viscoelastic of hyaluronic acid, selected from group containing chealon, viscoate or hyatulon, is transsclerally introduced into intraocular neoplasm structure using special purpose needle in dosed manner. The photosensitizing gel contains khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-1% by mass. Flexible polymer magnetolaser implant is extrasclerally introduced into the built tunnel in intraocular neoplasm projection zone under visual control using guidance beam. The implant has permanent ring-shaped magnet axially magnetized and producing permanent magnetic field of 3-4 mTesla units intensity, in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The implant is arranged with its north pole turned towards the intraocular neoplasm so that implant laser radiator lens is extrasclerally arranged in intraocular neoplasm projection zone. The implant light guide is sutured to sclera 5-6 mm far from the limb with single interrupted suture. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transscleral intraocular neoplasm laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm. The treatment course being over, the flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, neodymium-iron-boron or samarium-iron-nitrogen. 0.1-1% khlorin solution as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is additionally intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg and repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2 15-20 min later during 30-90 s.

EFFECT: complete destruction of neoplasm; excluded its further growth.

4 cl

FIELD: medicine.

SUBSTANCE: method involves applying transscleral diaphanoscopic examination method for adjusting intraocular neoplasm localization and size. Rectangular scleral pocket is built 2/3 times as large as sclera thickness which base is turned from the limb. Several electrodes manufactured from a metal of platinum group are introduced into intraocular neoplasm structure via the built scleral pocket. Next to it, intraocular neoplasm electrochemical destruction is carried out in changing electrodes polarity with current intensity of 100 mA during 1-10 min, and the electrodes are removed. Superficial scleral flap is returned to its place and fixed with interrupted sutures. 0.1-2% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transpupillary laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2. the operation is ended with placing sutures on conjunctiva. Platinum, iridium or rhodium are used as the metals of platinum group. The number of electrodes is equal to 4-8. 0.1-1% khlorin solution, selected from group containing photolon, radachlorine or photoditazine, is additionally repeatedly intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2.

EFFECT: complete destruction of neoplasm; excluded tumor recurrence; reduced risk of tumor cells dissemination.

3 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: the present innovation deals with treating vascular cutaneous neoplasms, such as nevus flammeus and gemangiomas. Light-thermal impact at energy ranged 39-47 J/sq. cm should be performed in two stages, and between them, 2-3 wk after the onset of vascular resistance at the first stage one should perform beta-therapy daily for 2-3 d at single dosage being 20 g. Then, 3 wk later it is necessary to conduct the second stage of light-thermal impact by starting at energy value being 42 J/sq. cm, not less. The method enables to shorten therapy terms due to applying combined method to affect vascular cutaneous neoplasms.

EFFECT: higher therapeutic and cosmetic effect.

1 ex

FIELD: medicine.

SUBSTANCE: method involves intravitreously introducing two electrodes into intraocular neoplasm after carrying out vitrectomy and retinotomy to expose the intraocular neoplasm. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with current intensity of 100 mA during 1-10 min or 10 mA during 10 min in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2.The transformed retina and tumor destruction products are intravitreally removed. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. Another embodiment of the invention involves adjusting position and size of the intraocular neoplasm in trans-scleral diaphanoscopic way. Rectangular scleral pocket is built above the intraocular neoplasm to 2/3 of sclera thickness with its base turned away from limb. Several electrodes are introduced into intraocular neoplasm structure via the built bed. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with the same current intensity in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. Superficial scleral flat is returned to its place and fixed with interrupted sutures. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg after having carried out vitrectomy and retinotomy. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2. The transformed retina and tumor destruction products are intravitreally removed using vitreotome. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. The number of electrodes is equal to 4-8.

EFFECT: reduced risk of metastasizing.

4 cl, 13 dwg

FIELD: medicine.

SUBSTANCE: method involves building tunnel to posterior eyeball pole in inferoexterior and superexterior quadrants. The tunnel is used for implanting flexible polymer magnetolaser implant to the place, the subretinal neovascular membrane is localized. The implant has a permanent magnet shaped as a cut ring and is provided with drug delivery system and a short focus scattering lens of laser radiator connected to light guide. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 5-7 mTesla units intensity. It is arranged with its north pole turned towards sclera at the place of the subretinal neovascular membrane projection with extrascleral arrangement of laser radiator lens membrane being provided in the subretinal neovascular membrane projection area. The other implant end is sutured to sclera 5-6 mm far from the limb via holes made in advance. The implant is covered with conjunctiva and retention sutures are placed thereon. Light guide and drug supply system lead is attached to temple with any known method applied. Drugs are supplied via the implant drug supply system in retrobulbary way in any order. Triombrast is given in the amount of 0,4-0,6 ml and dexamethasone or dexone in the amount of 0,4-0,6 ml during 3-4 days every 12 h. 0.1-1% aqueous solution of khlorin is intravenously introduced at the third-fourth day after setting the implant as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, at a bolus dose of 0.8-1.1 mg/kg. Visual control of subretinal neovascular membrane cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the subretinal neovascular membrane with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at general dose of 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the subretinal neovascular membrane via laser light guide and implant lens, repeated laser irradiation of the subretinal neovascular membrane is carried out with radiation dose of 30-60 J/cm2.

EFFECT: accelerated subretinal edema and hemorrhages resorption; regression and obliteration of the subretinal neovascular membrane; prolonged vision function stabilization.

6 cl

FIELD: medicine.

SUBSTANCE: method involves filling vitreous cavity with perfluororganic compound. Two electrodes manufactured from platinum group metal are intravitreally, transretinally introduced into intraocular neoplasm. Electrochemical destruction is carried out with current intensity of 10-100 mA during 1-10 min in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2 in perfluororganic compound medium. The transformed retina and tumor destruction products are intravitreally removed with perfluororganic compound volume being compensated with its additional introduction. Boundary-making endolasercoagulation of retinotomy area is carried out. The perfluororganic compound is substituted with silicon oil. The operation is ended in placing sutures over sclerotmy areas and over conjunctiva. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity. Platinum, iridium or rhodium are used as the platinum group metals.

EFFECT: complete destruction of neoplasm; reduced dissemination risk.

6 cl, 12 dwg

FIELD: medicine, applicable for stopping of pains of various nature.

SUBSTANCE: the device has a quantum-mechanical oscillator located in a casing, magnet, vessel for medicinal agent and a hollow cylinder. The magnet is installed between the oscillator and the vessel. Positioned in the vessel is a hollow cylinder having through holes on its surface.

EFFECT: quick and absolute anestesia.

2 ex, 1 dwg

FIELD: medicine.

SUBSTANCE: method involves administering laser radiation therapy once a day using low intensity pulsating radiation of wavelength equal to 890nmand power density of 0.03 mW/cm2. Injured organ projection to frontal abdominal wall is exposed to radiation at the first laser therapy stage in two fields acting upon each field for 2 min with radiation pulse succession frequency equal to 80 Hz in applying stable contact-type method. Total treatment dose on two fields is equal to 0.008 J/cm2. The second laser therapy stage begins immediately after having finished the first one in applying radiation along the large intestine path using labile contact-type method in a way that radiation pulse succession frequency equal to 80 Hz is applied first during 1 min and then frequencies of 600, 150 and 300 Hz are applied also during 1 min, respectively. Total treatment dose is equal to 0.032 J/cm2 at the second stage. Total treatment dose is equal to 0.04 J/cm2 at both stages.

EFFECT: enhanced effectiveness in inhibiting dysbacteriosis; reduced frequency of postoperative complications.

Up!